Pharmaguy's Insights Into Drug Industry News
194.4K views | +0 today
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy!

Docs Take Pharma Money to Hype Cancer Drugs on Twitter & Don't Disclose It!

Docs Take Pharma Money to Hype Cancer Drugs on Twitter & Don't Disclose It! | Pharmaguy's Insights Into Drug Industry News |

Some cancer doctors use Twitter to promote drugs manufactured by companies that pay them, but they almost never disclose their conflicts of interest on the social media platform, a new study shows.


“This is a big problem,” said senior author Dr. Vinay Prasad, a professor at Oregon Health and Science University in Portland. “Doctors are directly telling patients about their views on drugs, and financial conflict plays a role. But they’re not telling patients they have a conflict.”


Prasad and his colleagues analyzed the tweets and income of blood cancer specialists who posted regularly on Twitter and received at least $1,000 from drug manufacturers in 2014.


Of the 156 hematologist-oncologists in the study, 81 percent mentioned at least one drug from a company that gave them money, and 52 percent of their tweets mentioned the conflicted drugs, according to a study reported in a letter in The Lancet.


Earlier this year, Prasad published his first study on tweeting doctors. Nearly 80 percent of more than 600 U.S. hematologist-oncologists who tweeted had a conflict, his report in JAMA Internal Medicine found.


Celebrities use the hashtag #sponsored when they tweet about products from companies that pay them, Prasad said.


“Maybe we can learn something from the celebrities here,” he said.

rosywills's comment, September 22, 2017 4:01 AM
Cancer Immunotherapy Market is expected to reach USD 119.39 Billion by 2021
Download Free Brochure @
Scooped by Pharma Guy!

Pharmaguy's Searchable Twitter Archive from 2008 to Today

Pharmaguy's Searchable Twitter Archive from 2008 to Today | Pharmaguy's Insights Into Drug Industry News |

Over 25,000 Tweets going back to 2008! 

No comment yet.
Scooped by Pharma Guy!

ARIAD Pharmaceuticals' Public Twitter Policy

ARIAD Pharmaceuticals' Public Twitter Policy | Pharmaguy's Insights Into Drug Industry News |

ARIAD, like many biopharmaceutical companies, is in the process of engaging in conversations via new social media channels like Twitter.

About @ARIADPharm:
  • Welcomes your mentions/replies and we’ll do our best to respond to most questions. We will not respond to personal attacks, foul language, disparaging comments or topics that do not relate directly to the company. We may not be able to respond to your questions immediately and some responses may be limited in nature.
  • May not be able to address some questions/comments, including questions directly related to financial matters, ongoing legal matters, regulatory issues or certain other elements of our business.
  • Hopes that your contributions will add value to the overall dialogue and we appreciate you providing links or other resources to support any claims.
  • Any personal medical issues should be addressed with your physician rather than the Twitter account, which is not moderated by clinicians.
  • Twitter accounts that ARIAD follows or is followed by do not indicate an endorsement of the account owner or their products and services.
  • ARIAD may provide links or references to other sites as part of its Tweets. However, ARIAD claims no responsibility for the content of such other sites and shall not be liable for any damages or injury arising from that content. Any links to other sites are provided as merely a convenience to the users of this platform.
Pharma Guy's insight:

Back in June, 2014, I praised Aruad: "It's refreshing to see a social media policy published by a pharma company. I recently praised Boehringer Ingelheim's video social media policy (see Gefällt Mir! Boehringer Ingelheim Invites Two-Way Communication Via Social Media). Most large pharma companies (e.g., Pfizer) do not do this although they boast of having policies that the public cannot access (read Pfizer, Show Us Your Social Media "Playbook")."


But since the company raised the price of its leukemia treatment 4 or more times in a year to meet investor expectations (read Wall Street is Fueling Drug Price Hikes, Not "Benefit to Patients" as Claimed by Ariad & Other #pharma Companies;, I have to reconsider how I rate the social media savviness of pharma companies and bring into it their general attitude towards patients as well. 

MedHawk's curator insight, June 25, 2014 1:30 PM

Social media is changing the nature and atmosphere of health care interface between customers and pharmaceutical companies. The transformation of information gathering and the emergence of the engaged patient has demonstrated the increased importance of social media in the broader healthcare context. ARIAD, like many biopharmaceutical companies, is currently in the process of establishing conversations via Twitter.


It is apparent that a growing percentage of today’s patients are increasingly using digital tools as part of their overall health maintenance. In a recent survey, 51% of patients say they’d feel more valued as a patient via digital health communications, and another survey indicates that 41% of people said social media would affect their choice of healthcare provider.


These communications are important for pharmaceutical companies to have more understanding and awareness of what is important to the patients and those whose lives are affected by cancer. For ARIAD, social media allows customers to ask questions anonymously without feeling embarrassed to ask. This is a key technique to establish consumer trust for the company.


Scooped by Pharma Guy!

"Pharma Bro" Martin Shkeli Suspended from Twitter But Not for Raising Drug Prices

"Pharma Bro" Martin Shkeli Suspended from Twitter But Not for Raising Drug Prices | Pharmaguy's Insights Into Drug Industry News |

Martin Shkreli, the former Turing Pharmaceuticals executive who became known as ‘‘Pharma Bro’’ after he dramatically hiked the price of a drug, was suspended from Twitter on Sunday afternoon. A person at Twitter who is familiar with the matter but declined to be quoted directly confirmed that Shkreli’s suspension was related to his harassment of journalist Lauren Duca.

Duca, a freelance journalist, recently wrote a viral op-ed for Teen Vogue titled ‘‘Donald Trump is gaslighting America.’’ During a combative appearance on Tucker Carlson’s Fox News show just before Christmas, Carlson told Duca that she should stick to writing about ‘‘thigh-high boots,’’ and Duca told Carlson that he was ‘‘unprofessional’’ and a ‘‘partisan hack.’’ The exchange resulted in her receiving thousands of angry messages, including a rape threat on Christmas Day.

A few days ago, Shkreli started trolling Duca on Twitter.


Further Reading:

No comment yet.
Scooped by Pharma Guy!

How Do You Measure Social Media Content Effectiveness?

How Do You Measure Social Media Content Effectiveness? | Pharmaguy's Insights Into Drug Industry News |

Social media provides brands with another channel for content sharing. But as this becomes the norm, content marketers are looking to the next step in the process: measuring the effectiveness of this content. Based on an April 2014 study conducted by Ipsos OTX for the Association of National Advertisers (ANA), the overwhelming majority of brands are now doing so.

According to the research, 80% of US client-side marketers measured the effectiveness of their social content, with social media metrics such as “likes” the most common. Usage statistics—daily or monthly active users, for example—fell in the middle of the list. Meanwhile, metrics that could identify business ramifications were not used nearly as much, with financially based measurements such as return on investment and sales landing near the bottom.

Pharma Guy's insight:

See how Boehringer Ingelheim measures success of its disease awareness TweetChats. It's in their "How to" playbook reviewed in this Pharma Marketing News article: 

How to Host a Successful Pharma TweetChat

No comment yet.
Scooped by Pharma Guy!

Thinking Outside the Tweet

Thinking Outside the Tweet | Pharmaguy's Insights Into Drug Industry News |

I couldn't sleep last night. For some reason I became obsessed with trying to figure out a way that pharma companies can create Rx branded tweets that satisfy FDA's recent "Industry Guidance for Internet/Social Media Platforms with Character Space Limitations — Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices."

Pharma Guy's insight:

"The draft guidance does not mention Tweets accompanied by images, which is perhaps a way to present ISI along with benefit information in the tweet itself," I said. "I have created a mock-up using Lipitor as an example."

Here's a screen shot of how this tweet would look on Twitter (would it pass muster with FDA? Tell me your opinion on Pharma Marketing Blog).

No comment yet.